Tc 99m exametazime - Jubilant DraxImage

Drug Profile

Tc 99m exametazime - Jubilant DraxImage

Alternative Names: Drax Exametazime; Technetium 99m exametazime - Jubilant DraxImage; Technetium Tc 99m exametazime - Jubilant DraxImage

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jubilant DraxImage
  • Class Oximes; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Intra-abdominal infections; Irritable bowel syndrome

Most Recent Events

  • 18 Jan 2018 Jubilant DraxImage anticipates Tc 99m exametazime launch in USA in March 2018 (Email communication with Jubilant DraxImage)
  • 07 Sep 2017 Chemical structure information added
  • 17 Aug 2017 Registered for Intra-abdominal infections (Diagnosis) in USA (IV) (US FDA Approval letter, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top